Literature DB >> 8629459

Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives.

C Bieglmayer1, G Hofer, C Kainz, A Reinthaller, B Kopp, H Janisch.   

Abstract

In a pilot study we investigated the association between concentrations of various eicosanoids in menstrual blood with pain and oral contraceptive use. Menstrual fluid was collected on tampons by 12 women who did not use an oral contraceptive but suffered from slight primary dysmenorrhea and by three pain-free women who used an oral contraceptive. Eicosanoids (cyclooxygenase products: 6-ketoprostaglandin F1 alpha, thromboxane B2, prostaglandin E2, prostaglandin F2 alpha, 13,14-dihydro-15-ketoprostaglandin F2 alpha, 12-hydroxy-heptadecatrienoic acid; lipoxygenase products: 5-, 12-, 15-hydroxy-eicosatetraenoic acid (HETE), leukotriene B4, leukotriene C4, leukotriene D4, leukotriene E4) and female sex steroids (17 beta-estradiol and progesterone) were analyzed by the combined use of high-performance liquid chromatography and radioimmunoassay. 12-HETE was the main arachidonic acid metabolite. An increased metabolism of arachidonic acid was associated with pain, especially when synthesis of 12-HETE was elevated. Oral contraceptive use decreased the synthesis of prostaglandins as well as leukotrienes. The concordant changes of cyclooxygenase and lipoxygenase products in dysmenorrhea or in oral contraceptive use may be explained by an increased or decreased phospholipid metabolism, respectively.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8629459     DOI: 10.3109/09513599509160464

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

1.  Menstrual pain and epithelial ovarian cancer risk.

Authors:  Ana Babic; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2014-09-05       Impact factor: 2.506

Review 2.  A contemporary approach to dysmenorrhea in adolescents.

Authors:  Zeev Harel
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression.

Authors:  Lawrence A Olatunji; Young-Mi Seok; Adedoyin Igunnu; Seol-Hee Kang; In-Kyeom Kim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-22       Impact factor: 3.000

Review 4.  Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment.

Authors:  Folabomi A Oladosu; Frank F Tu; Kevin M Hellman
Journal:  Am J Obstet Gynecol       Date:  2017-09-06       Impact factor: 8.661

5.  Effect of Zingiber officinale R. rhizomes (ginger) on pain relief in primary dysmenorrhea: a placebo randomized trial.

Authors:  Parvin Rahnama; Ali Montazeri; Hassan Fallah Huseini; Saeed Kianbakht; Mohsen Naseri
Journal:  BMC Complement Altern Med       Date:  2012-07-10       Impact factor: 3.659

6.  An Investigation of the Molecular Mechanisms Underlying the Analgesic Effect of Jakyak-Gamcho Decoction: A Network Pharmacology Study.

Authors:  Ho-Sung Lee; In-Hee Lee; Kyungrae Kang; Sang-In Park; Tae-Wook Kwon; Dae-Yeon Lee
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-01       Impact factor: 2.629

7.  Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data.

Authors:  Jayne E Edwards; R Andrew Moore; Henry J McQuay
Journal:  BMC Womens Health       Date:  2004-07-20       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.